問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

曾令民

List

118Cases

2016-09-01 - 2020-11-09

Phase II

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY.

  • Condition/Disease

    HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

  • Test Drug

    KADCYLA

Participate Sites
10Sites

Terminated8Sites

侯明鋒
Kaohsiung Municipal Gangshan Hospital

未分科

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2016-02-21 - 2020-12-31

Phase III

A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE NEGATIVE BREAST CANCER

  • Condition/Disease

    Triple Negative Breast Cancer (TNBC)

  • Test Drug

    Atezolizumab

Participate Sites
6Sites

Not yet recruiting1Sites

Terminated3Sites

侯明鋒
Kaohsiung Municipal Gangshan Hospital

未分科

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2014-04-01 - 2018-12-19

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2013-12-01 - 2021-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2021-02-08 - 2023-07-20

Phase III

A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease

  • Condition/Disease

    ER (+), HER2 (-) breast cancer

  • Test Drug

    SAR439859

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2010-08-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-08-01 - 2013-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2014-06-01 - 2018-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2014-12-01 - 2021-04-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2014-12-01 - 2019-08-13

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 7 8 9 10 11 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB